In this study, we used ZDF rats to successfully address the hypothesis that imeglimin, a novel therapeutic agent, could ameliorate the loss of insulin secretory capacity and β‐cell mass in the context of severe diabetes. This evidence concerns the gene INS and diabetes mellitus.